STOCK MARKET BSE NSE

Cipla arm InvaGen Pharma gets USFDA nod for neuropathic pain management drug

Quoting IQVIA data, Cipla said Lyrica had an estimated market size of USD 5.4 billion for 12 months ending March 2019.

Published: 22nd July 2019 04:09 PM  |   Last Updated: 22nd July 2019 04:09 PM   |  A+A-

An employee works at the reception area of Cipla at its headquarters in Mumbai, India June 17, 2015. | Reuters

By PTI

NEW DELHI: Drug major Cipla Monday said its subsidiary InvaGen Pharmaceuticals has received final approval from the US health regulator for Pregabalin Capsules, indicated for management of neuropathic pain associated with certain illnesses.

InvaGen has received approval from the the United States Food and Drug Administration (USFDA) for the drug in the strengths of 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg and 300mg, Cipla said in a regulatory filing. Cipla said the approved product is a generic therapeutic equivalent version of Pfizer's Lyrica.

Pregabalin capsules are indicated for management of neuropathic pain associated with diabetic peripheral neuropathy, management of postherpetic neuralgia, adjunctive therapy for the treatment of partial onset seizures in patients 17 years of age and older, management of fibromyalgia and management of neuropathic pain associated with spinal cord injury.

Quoting IQVIA data, Cipla said Lyrica had an estimated market size of USD 5.4 billion for 12 months ending March 2019.

The product is available for shipping immediately, the company added. Shares of Cipla were trading 0.18 per cent lower at Rs 535.90 apiece on the BSE.

Stay up to date on all the latest Business news with The New Indian Express App. Download now

Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp